A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Routine Clinical Care in Patients With Epilepsy

Trial Profile

A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Routine Clinical Care in Patients With Epilepsy

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Perampanel (Primary)
  • Indications Epilepsy
  • Focus Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 28 Apr 2017 Results of exploratory analysis assessing the potential of perampanel as monotherapy using data from two prospective open-label extension studies (NCT00735397 and NCT01161524) and a retrospective study (NCT02736162), presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 13 Apr 2017 According to an Eisai Inc media release, results assessing perampanel as monotherapy from studies (307, 235 and 504) will be presented at the American Academy of Neurology (AAN) Annual Meeting.
    • 06 Dec 2016 Status changed from not yet recruiting to completed, as per the results published at the 70th Annual Meeting of the American Epilepsy Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top